Daktacort 2% 1% Cream
- Name:
Daktacort 2% 1% Cream
- Company:
Janssen Sciences Ireland
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 02/10/19
(Click to Download)Click on this link to Download PDF directly
Janssen Sciences Ireland
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 2 October 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 12 April 2019 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 12 April 2019 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 9 May 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 4 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 3 May 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
1. Addition of the following in section 4.4:
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
2. Addition Vision, 'blurred (also see section 4.4)' in section 4.8 under System Organ Class 'Eye disorders' with frequency of 'Not Known'.
Updated on 12 November 2015 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 12 November 2015 PIL
Reasons for updating
- New PIL for new product
Updated on 12 November 2015 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated section 4.8 side effect reporting statement to reflect change from IMB to HPRA.
Updated on 12 November 2015 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 23 May 2014 SmPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.2 - Incompatibilities
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
4.2: Wording added re duration of treatment, thinning of the skin and paediatrics
4.3: Additional contraindication
4.4: Contact should be avoided with latex products
4.6: Embryotoxic at maternal toxic doses. Breast-feeding section added.
4.9: Skin irritation with prolonged use. Removal of gastric empyting.
5.1: ATC code added. Clinical efficacy information added and information on hydrocortisone
6.2: Contact should be avoided with latex products
10: 22 May 2014
Updated on 22 May 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to date of revision
Updated on 1 May 2014 SmPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
4.6: clarification of wording
4.8: Term 'ADR' changed to 'adverse reaction' and addition of reporting of suspected adverse reactions wording
6.1: spelling correction to disodium edetate
10: 29 April 2014
Updated on 29 April 2014 PIL
Reasons for updating
- Change of contraindications
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 14 January 2013 PIL
Reasons for updating
- Change of contraindications
- Change to date of revision
- Correction of spelling/typing errors
Updated on 21 June 2011 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Addition of hypersenstivityt warning, advice not to come into contact with eye, warning to avoid long-term treatment. Advice that synthetic materila may be damaged if they come into contact with th cream.
Section 4.6 reference to animal studies.
Section 4.8: update to AADR table.
Section 5.2: additional statement regardin absorption in infants.
Section 5.3: Additioh of pre-clinical safety data, originall 'non stated'
Updated on 15 June 2011 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
Updated on 8 January 2010 PIL
Reasons for updating
- Change to date of revision
- Change to improve clarity and readability
Updated on 19 January 2009 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
|
4.5 |
Interaction with other medicinal products and other forms of interaction |
Addition of possible interaction with oral hypoglycaemics and phenytoin. Addition of the statement that miconazole can decrease the rate of metabolism of hydrocortisone. |
|
4.8 |
Undesirable effects |
Addition of postmarketing spontaneous report table. |
|
5.2 |
Pharmacokinetic properties |
Addition of Absorption, Distribution and Metabolisn and elimination data |
|
10. |
DATE OF REVISION OF THE TEXT |
Changed to 28th October 2008 |
Updated on 19 January 2009 PIL
Reasons for updating
- Change to side-effects
- Change to drug interactions
- Change to date of revision
Updated on 4 July 2008 PIL
Reasons for updating
- Addition of marketing authorisation holder
Updated on 4 July 2008 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
|
7. |
MARKETING AUTHORISATION HOLDER
|
Changred from Saunderton address to 50-100 Holmers Farm Way, High Wycombe, Buks, HP12 4EG, UK |
|
10. |
DATE OF REVISION OF THE TEXT |
Changed to 30th June 2008 |
Updated on 19 July 2007 PIL
Reasons for updating
- Change of trade or active ingredient name
- Change of inactive ingredient
- Change of manufacturer
- Change to warnings or special precautions for use
- Change to storage instructions
- Change to date of revision
Updated on 18 July 2007 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.4 - Special precautions for storage
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
|
Change to section 1 – trade name NAME OF THE MEDICINAL PRODUCT
|
Daktacort™ 2% / 1% w/w Cream. |
|
Change to section 2 – quantitative and qualitative composition |
Miconazole nitrate 2% w/w and hydrocortisone 1% w/w. Contains 0.2% w/w benzoic acid (E210) and 0.0052% butylated hydroxyanisole (E320). For full list of excipients, see section 6.1 |
|
Change to section 3 – pharmaceutical form |
White, homogeneous, odourless cream. |
|
Change to section 4.4 – Special Warnings and Precautions for Use |
Continuous treatment for longer than three weeks should be avoided in infants because of the possibility of adrenocortical suppression. Adrenal suppression can occur even without the use of occlusive dressings. Daktacort cream contains benzoic acid, which is mildly irritant to the skin, eyes and mucous membranes. Daktacort cream also contains butylated hydroxanisole, which may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes. |
|
Change to section 6 – Pharmaceutical Particulars |
|
|
Change to section 6.1 – List of Excipients |
Disodium edentate . |
|
Change to section 6.2 - Incompatibilities |
Not applicable.. |
|
Change to section 6.3 – Shelf Life |
|
|
Change to section 6.4 – Special Precautions for Storage |
Store in a refrigerator ( 2-8°C). |
|
Change to section 6.5 – Nature and Contents of Container |
|
|
Change to section 6.6 – Instructions for use, handling and disposal |
No special requirements. |
|
Change to section 7 – Marketing Authorisation Holder |
|
|
Change to section 8 – MA number |
|
|
Change to section 9 – Date of Renewal of Authorisation |
16 December 1996 / 16 December 2006 |
Updated on 14 June 2007 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
|
Change to section 4.2 – Posology and Method of Administration |
For topical administration changed to For cutaneous administration |
|
Change to section 4.4 – Special Warnings and Precautions for Use |
Addition of: As with any topical corticosteroid, care is advised with infants and children when Daktacort is to be applied to extensive surface areas or under occlusive dressings including baby napkins. Similarly application to the face should be avoided. Continuous treatment for longer than three weeks should be avoided in infants because of the possibility of adrenocortical suppression. Adrenal suppression can occur even without the use of occlusive dressings. |
|
Change to section 4.6 – Pregnancy and Lactation |
The product should not be used during pregnancy unless considered essential by the physician. Addition of; Caution is also recommended during lactation. Treatment of large surfaces and the application under occlusive dressing should be avoided during that time. |
|
Change to section 10 – Date of revision of the text |
June 2007 |
Updated on 4 September 2006 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 6.1 - List of excipients
- Change to section 6.4 - Special precautions for storage
- Change to section 7 - Marketing authorisation holder
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
|
1. |
NAME OF THE MEDICINAL PRODUCT
|
Daktacort™ Cream. – Name no longer upper case |
|
2. |
QUALITATIVE AND QUANTITATIVE COMPOSITION
|
Miconazole nitrate 2% w/w and hydrocortisone 1% w/w. For excipients, see section 6.1. For excipients, see section 6.1. – has been added |
|
3. |
PHARMACEUTICAL FORM |
Cream. The cream is white and homogeneous. The cream is white and homogeneous. – has been added |
|
4.5 |
Interaction with other medicinal products and other forms of interaction |
None stated Changed from Not applicable |
|
6.1 |
List of excipients |
Macrogol ester Oleoyl macroglycerides Ph. Eur. Liquid paraffin Benzoic acid (E210) Sodium edentate Ph.Eur. Butylated hydroxyanisole (E320) Purified water |
|
6.4 |
Special precautions for storage |
Store at 2-8°C. ‘in a refrigerator’ removed |
|
7. |
MARKETING AUTHORISATION HOLDER
|
Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ UK UK added |
|
9. |
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION |
16 December 1996 / 16 December 2001 |
|
10. |
DATE OF REVISION OF THE TEXT |
August 2005 |
Updated on 20 September 2005 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 9 August 2004 SmPC
Reasons for updating
- Improved electronic presentation
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 25 May 2004 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5 - Pharmacological properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 21 July 2003 SmPC
Reasons for updating
- Improved electronic presentation
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 5 June 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may be renewed (B)